Webinar: Webinar: Producing High Quality CRISPR-Cas9 Edited hiPSCs

Experimental studies using hiPSCs can experience high inter- and intra-experimental variability further fueling the reproducibility crisis in life sciences. In a recent webinar, speakers showcased a solution using a bioreactor system, achieving consistent and high-quality hiPSC-derived cardiomyocytes.

The featured speakers used a stirred suspension bioreactor system to create an optimal environment for cell growth and differentiation. This enabled them to create a unified differentiation protocol that can be applied to a variety of hiPSCs (patient and control lines) with high cardiomyocyte content and reduced batch-to-batch variability. Using a wide array of cardiac disease modeling assays, they then confirmed high reproducibility of cryo-preserved hiPSC-derived cardiomyocytes.